Scientists at the University of Sheffield have found a new drug adrenomedullin-2 receptor antagonists which could improve life expectancy and quality for patients with hard-to-treat cancers, such as pancreatic cancer and relapsed breast cancer.
The researchers founded the spin-out company Modulus Oncology, along with a team of experienced biotech entrepreneurs, to fast-track the drug into clinical testing within two years. Read more . . .